Correlation of clinical parameters with risk groups in the test cohort (n = 181)
| Characteristic . | Low risk, % . | High risk, % . | P . |
|---|---|---|---|
| Age, 65 y or older | 30 | 23 | .692 |
| Albumin, less than 35 g/L | 17 | 32 | .163 |
| β2-microglobulin | |||
| Less than 297.5 nM | 57 | 32 | .005 |
| 297.5 nM to less than 467.5 nM | 23 | 18 | |
| 467.5 nM or more | 19 | 50 | |
| C-reactive protein, 4 mg/L or above | 44 | 59 | .271 |
| LDH, 190 IU/L or above | 18 | 59 | < .001 |
| Cytogenetic abnormalities | 27 | 77 | < .001 |
| GEP-based translocations | |||
| CCND1 | 14 | 0 | < .001 |
| MMSET | 12 | 23 | |
| MAF/MAFB | 7 | 36 | |
| No spike | 67 | 41 | |
| Characteristic . | Low risk, % . | High risk, % . | P . |
|---|---|---|---|
| Age, 65 y or older | 30 | 23 | .692 |
| Albumin, less than 35 g/L | 17 | 32 | .163 |
| β2-microglobulin | |||
| Less than 297.5 nM | 57 | 32 | .005 |
| 297.5 nM to less than 467.5 nM | 23 | 18 | |
| 467.5 nM or more | 19 | 50 | |
| C-reactive protein, 4 mg/L or above | 44 | 59 | .271 |
| LDH, 190 IU/L or above | 18 | 59 | < .001 |
| Cytogenetic abnormalities | 27 | 77 | < .001 |
| GEP-based translocations | |||
| CCND1 | 14 | 0 | < .001 |
| MMSET | 12 | 23 | |
| MAF/MAFB | 7 | 36 | |
| No spike | 67 | 41 | |